In the SOLOIST-WHF (Effect of Sotagliflozin on Cardiovascular Events in Patients with Type 2 Diabetes Post Worsening Heart Failure) clinical trial, sotagliflozin, a dual SGLT1/SGLT2 antagonist, substantially reduced the incidence of fatal cardiovascular events, hospitalizations, and urgent visits for HF among diabetic patients with worsening HF compared to placebo [18]. This evidence concerns the gene SLC5A2 and hydrops fetalis.